Toleriane Ultra Reno in Allergic Subjects With Skin Intolerance to Their Usual Cosmetic
NCT ID: NCT05487937
Last Updated: 2022-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
109 participants
OBSERVATIONAL
2021-05-25
2021-09-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This open-labeled, multicenter study was conducted under dermatological control in Caucasian subjects above 16 years of age with an allergic background and intolerance to cosmetics lasting for at least 2 years prior to inclusion. The dermocosmetic product was to be applied on the entire face twice daily for 28 days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Exposure to Cosmetics on Sensitive Skin
NCT03958968
Skin Irritation Test of Ten Products
NCT05245383
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
NCT02117739
To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
NCT04007159
Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity
NCT02441608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each study report is subjected to a quality inspection by a member of Dermscan. A certificate of quality inspection signed by a proofreader (not involved in the audited study) is enclosed in each study. The inspection of the study report allows to confirm that the results reflect exactly the study raw data and that the study fulfills any standard and regulatory requirements.
With regard to the statistical analysis, the continuous data is summarized using the following statistics by time point (Day0, Day14, Day28): number of values, mean, median, standard deviation, minimum value, maximum value. For each continuous data obtained from devices (Tewameter for Transepidermal water loss, Corneometer for cutaneous hydration measurements), a mixed linear model for repeated measurements is adjusted to raw data, including the factor "time" as fixed (with 3 levels: Day0, Day14, Day28) and the factor "subject" as random. Using the adjusted means obtained from this model (LS-Means), the contrast of interest is built to assess the change from baseline (Day0) at each point (Day14 and D28). For the categorical data, the global tolerance scores by both the investigator and the participant assessed using a 4-point scale are summarized in frequency (N) and percentage (%) by time point (Day14, D28) with associated 95% confidential interval. For other categorical data, a Wilcoxon signed rank test is carried out for each parameter assessed using an ordinal scale:
* Sensiscore (erythema, irritation, stinging, itching, burning, tightening, discomfort) assessed using a 5-point structured scale of frequency and intensity of the functional signs.
* Composite score of the skin state (redness, pruritus, dryness, burning sensation, tingling) assessed using a 4-point structured scale.
* Smoothing effect assessed using a 4-point structured scale.
The participants have the right to exit from the study at any time and for any motive, in compliance with the Helsinki Declaration (1964) and its successive updates. The investigator can also interrupt the person's participation in the study prematurely in the case of a disease occurrence, a pregnancy or the occurrence of an adverse reaction.
Every premature exit must be classified under one of the following headings:
* presence of non-inclusion criteria;
* Undesirable Effect / Adverse Event occurrence;
* Serious Adverse Event / Serious Adverse Effect occurrence;
* withdrawal of consent;
* lost to follow-up;
* the appearance of non-inclusion criteria;
* non-adherence to the protocol;
* other reason.
All the adverse events and serious adverse events are reported in the case report form and the study report.
No replacement is foreseen as 10% additional participants are planned to be included in the study (110 included participants in order to obtain results on 100 (+/- 10%) participants minimum.). An identification code is attributed to each participant for the purpose to keep his/her identity confidential.
The personnel in charge of the study collects data into individual case report forms in electronic or paper format and/or directly from measurement software. When information is collected in paper format, the double data entry is then done from these supports by the designed operator(s), without any interpretation, in specific EXCEL databases. The Project Manager or assistant checks the double data entry by comparing both databases. Then the coherence of the whole data set is checked as well as formulas used in the EXCEL tables (calculation formulas, selected data…). When all the controls are done, the database is locked.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Toleriane Ultra
Participants are asked to apply the study product twice daily (morning and evening) at home for 28 days.
Use of Toleriane Ultra to relieve face allergic skin
The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Use of Toleriane Ultra to relieve face allergic skin
The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* caucasian
* phototype I to IV
* participants presenting with an allergy ground
* participants without visible allergic dermatosis at inclusion on the face
* participants having skin intolerance with cosmetic care
* participants who have not changed their cosmetic habits for less than 15 days
Exclusion Criteria
* cutaneous pathology on the studied zone
* use of topical or systemic treatment during the previous weeks liable to interfere with assessment of the cutaneous acceptability of the study product
* professional facial care during the study or within the previous month
* excessive exposure to sunlight or UV-rays within the previous month
* participant having undergone surgery under general anesthesia within the previous month
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cosmetique Active International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Czermanska
Role: STUDY_DIRECTOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermscan Poland Sp. z o. o.
Gdansk, , Poland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kerob D, Czermanska A, Karamon EM, Moga A, Lecerf G, Niore M, Le Dantec G, Le Floc'h C, Tan J. A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin. Clin Cosmet Investig Dermatol. 2023 Jul 11;16:1787-1794. doi: 10.2147/CCID.S418483. eCollection 2023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LRP20006-TOLERIANE ULTRA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.